WallStSmart

Amgen Inc (AMGN)vsTrane Technologies plc (TT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amgen Inc generates 72% more annual revenue ($37.22B vs $21.60B). AMGN leads profitability with a 21.0% profit margin vs 13.4%. AMGN appears more attractively valued with a PEG of 2.17. AMGN earns a higher WallStSmart Score of 62/100 (C+).

AMGN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 5.0
Piotroski: 4/9

TT

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 4.3Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNFair Value (-2.3%)

Margin of Safety

-2.3%

Fair Value

$322.08

Current Price

$331.11

$9.03 premium

UndervaluedFair: $322.08Overvalued

Intrinsic value data unavailable for TT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.2/10
Return on EquityProfitability
101.3%10/10

Every $100 of equity generates 101 in profit

Operating MarginProfitability
33.8%10/10

Strong operational efficiency at 33.8%

Market CapQuality
$178.00B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

Free Cash FlowQuality
$1.48B8/10

Generating 1.5B in free cash flow

TT2 strengths · Avg: 9.5/10
Return on EquityProfitability
36.6%10/10

Every $100 of equity generates 37 in profit

Market CapQuality
$107.57B9/10

Large-cap with strong market position

Areas to Watch

AMGN3 concerns · Avg: 4.0/10
PEG RatioValuation
2.174/10

Expensive relative to growth rate

Price/BookValuation
19.4x4/10

Trading at 19.4x book value

EPS GrowthGrowth
4.4%4/10

4.4% earnings growth

TT4 concerns · Avg: 3.5/10
PEG RatioValuation
2.394/10

Expensive relative to growth rate

P/E RatioValuation
37.2x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.6x4/10

Trading at 12.6x book value

EPS GrowthGrowth
-2.1%2/10

Earnings declined 2.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.

Bull Case : TT

The strongest argument for TT centers on Return on Equity, Market Cap.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.

Bear Case : TT

The primary concerns for TT are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

AMGN profiles as a mature stock while TT is a value play — different risk/reward profiles.

TT carries more volatility with a beta of 1.21 — expect wider price swings.

TT is growing revenue faster at 6.0% — sustainability is the question.

AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

AMGN scores higher overall (62/100 vs 52/100), backed by strong 21.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Trane Technologies plc

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Trane Technologies plc is an American Irish domiciled diversified industrial manufacturing company. It is headquartered near Dublin, Ireland.

Want to dig deeper into these stocks?